On Monday, March 28, the federal Centers for Medicare and Medicaid Services (CMS), through the CMS Office of the Actuary, released national health expenditure projections leading up to and including the year 2030. The projections show an average annual healthcare inflation rate of 5.1 percent from 2021-2030, with annual expenditures to reach nearly $6.8 trillion by 2030; because the gross domestic product (GDP) is also projected to grow by 5.1 percent annually during the same period, the percentage of GDP spent in 2030 is expected to be 19.6 percent in 3020, nearly identical to the 2020 share of 19.7 percent. That overall $6.8 trillion in annual national healthcare expenditures is in line with previous predictions in the past couple of years.
The announcement, a version of which was also published as an article in Health Affairs entitled “National Health Expenditure Projections, 2021-30: Growth To Moderate As COVID-19 Impacts Wane,” began thus: “Today, the Centers for Medicare & Medicaid Services (CMS) released the 2021-2030 National Health Expenditure (NHE) report, prepared by the CMS Office of the Actuary, that presents health spending and enrollment projections for the coming decade. The report notably shows that despite the increased demand for patient care in 2021, the growth in national health spending is estimated to have slowed to 4.2 percent, from 9.7 percent in 2020, as supplemental funding for public health activity and other federal programs, specifically those associated with the COVID-19 pandemic, declined significantly.”
The actuaries—named as John A. Poisal, Andrea M. Sisko, Gigi A. Cuckler, Sheila D. Smith, Sean P. Keehan, Jacqueline A. Fiore, Andrew, J. Madison, and Kathryn E. Rennie, wrote that “The NHE has been published annually since 1960, and is often referred to as the ‘official’ estimates of U.S. health spending. The historical and projected estimates of NHE measure total annual U.S. spending for the delivery of health care goods and services by type of good or service (hospital, physician, prescription drugs, etc.), type of payer (private health insurance, Medicare, Medicaid, etc.), and type of sponsor (businesses, households and federal/state governments). The NHE report also includes spending on government public health, investment in structures and equipment, and noncommercial research, as well as information on insurance enrollment and uninsured estimates.”
Further, they wrote, “The report finds that annual growth in national health spending is expected to average 5.1 percent over 2021-2030, and to reach nearly $6.8 trillion by 2030. Growth in the nation’s Gross Domestic Product (GDP) is also projected to be 5.1 percent annually over the same period. As a result of the comparable projected rates of growth, the health share of GDP is expected to be 19.6 percent in 2030, nearly the same as the 2020 share of 19.7 percent. Near-term expected trends in health spending and insurance enrollments are significantly influenced by the COVID-19 public health emergency (PHE). In 2021, spending for other federal programs and public health activity (the NHE Accounts categories that include the federal COVID-19 supplemental funding) is expected to have declined from $417.6 billion in 2020 to $286.8 billion. Additionally, following the declines observed in 2020, health care utilization is expected to rebound starting in 2021 and then normalize through 2024. As COVID-19 federal supplemental funding is expected to wane between 2021 and 2024, the government’s share of national health spending is expected to fall to 46 percent by 2024, down from an all-time high of 51 percent in 2020.”
Importantly, “The average annual growth in national health spending over the latter half of the next decade (2025-2030) is projected to be 5.3 percent and is expected to be driven primarily by more traditional elements, including economic, demographic, and health-specific factors. During this time, upward pressure on spending growth for Medicaid is expected, in part due to the expiration of Disproportionate Share Hospital payment cap reductions statutorily scheduled to end in 2027. Conversely, downward pressure on spending growth is expected for Medicare (related to the end of the Baby Boomers’ enrollments), as well as for private health insurance and out-of-pocket spending in lagged response to slowing income growth earlier in the period. The percentage of the population with health insurance is expected to be 91.1 percent in 2021 and 2022 (mainly due to gains in Medicaid enrollment that are, in large part, due to special rules in effect only during the COVID-19 PHE). After the end of the COVID-19 PHE, enrollments are projected to begin returning to pre-pandemic distributions. The 2030 insured rate is projected to be 89.8 percent.”
Further, they wrote, “Selected highlights in national health expenditures by major payer include:
Ø Medicare: Medicare spending growth is projected to average 7.2 percent over 2021-2030, the fastest rate among the major payers. Projected spending growth of 11.3 percent in 2021 is expected to be mainly influenced by an assumed acceleration in utilization growth, while growth in 2022 of 7.5 percent is expected to reflect more moderate growth in use, as well as lower fee-for-service payment rate updates and the phasing in of sequestration cuts. Spending is projected to exceed $1 trillion for the first time in 2023. By 2030, Medicare spending growth is expected to slow to 4.3 percent as the Baby Boomers are no longer enrolling and as further increases in sequestration cuts occur.
Ø Medicaid: Average annual growth of 5.6 percent is projected for Medicaid spending for 2021-2030. Medicaid spending growth is expected to have accelerated to 10.4 percent in 2021, associated with rapid gains in enrollment. Over 2022 and 2023, Medicaid spending growth is expected to slow to 5.7 percent and 2.7 percent, respectively, as a result of projected enrollment declines, after the end of the COVID-19 PHE, when the continuous enrollment condition under the Families First Coronavirus Response Act expires and states begin to disenroll beneficiaries no longer eligible for Medicaid. Over 2025-2030, spending growth is projected to increase an average 5.6 percent, in part due to the expiration of Disproportionate Share Hospital payment cap reductions set for late-2027. Spending is projected to exceed $1 trillion for the first time in 2028.
Ø Private Health Insurance and Out-of-Pocket: For 2021-2030, private health insurance spending growth is projected to average 5.7 percent. A rebound in utilization is expected to primarily influence private health insurance spending growth over 2021 (6.3 percent) and 2022 (8.3 percent), and then normalize through 2024. Over 2025-2030, as health spending trends by private payers tend to be influenced on a lagged basis by changes in income growth, average growth for private health insurance spending is then expected to slow to 4.8 percent by 2030 in response to slowing income growth earlier in the projection period. Out-of-pocket expenditures are projected to grow at an average rate of 4.6 percent over 2021-2030 and to represent 9 percent of total spending by 2030 (ultimately falling from its current historic low of 9.4 percent in 2020).
And, looking at the sectors in U.S. healthcare, the actuaries wrote: “Selected highlights in projected health expenditures for the three largest goods and services categories are as follows:
Ø Hospital: Hospital spending growth is projected to average 5.7 percent for 2021-2030. In 2021, hospital spending growth is expected to be 5.7 percent, a deceleration from 6.4 percent in 2020, largely due to declining federal supplemental payments. However, growth in hospital spending for Medicare, Medicaid, and private health insurance are expected to have grown faster compared to 2020 due to a partial rebound in utilization. Demand for care is expected to remain elevated in 2022, along with a projected acceleration in price growth; as a result, hospital spending growth is likewise expected to accelerate to 6.9 percent in 2022. Over 2023 and 2024, growth is expected to normalize (5.6 percent per year) and transition away from pandemic-related impacts on utilization, federal program funding, and changes in insurance enrollment, and remain similar on average through 2030 (5.5 percent per year). Key factors influencing hospital spending growth over 2025-30 is faster projected growth in Medicaid spending due to the scheduled expiration of Disproportionate Share Hospital payment cap reductions, as well as slower expected growth in Medicare spending (slower enrollment growth and larger sequestration-based cuts) and private health insurance spending (in lagged response to slowing income growth).
Ø Physician and Clinical Services: Physician and clinical services spending is projected to grow an average of 5.6 percent per year over 2021-2030. In 2021, growth in physician and clinical services spending is expected be 5.1 percent, which is slower than growth of 5.4 percent in 2020, mainly due to declines in supplemental funding more than offsetting expected utilization increases among Medicare and private health insurance enrollees. Consumers are expected to return to more typical use patterns in 2022 resulting in 6.2 percent growth. Pandemic-related effects are expected to diminish through 2024. Through 2030, average total physician and clinical services spending growth of 5.5 percent is expected to primarily reflect decelerating spending growth for private health insurance enrollees in lagged response to projected slower growth in incomes earlier in the period.
Ø Retail Prescription Drugs: Spending growth for retail prescription drugs is projected to increase over 2021-2030 at an average rate of 5 percent. In 2021, growth is expected to accelerate (4.7 percent) compared to 2020 (3 percent) due to faster growth in utilization by Medicaid beneficiaries and those enrolled in private health insurance. In 2022, however, overall retail prescription drug spending growth is projected to slow to 4.3 percent, as declines in Medicaid enrollment are expected to lead to slower drug spending for that program and more than offset faster Medicare spending for drugs in that year. New drugs expected to be approved from 2021-2026 are expected to influence retail prescription drug spending utilization and prices over the remainder of the projection period; over 2025-2030, retail prescription drug spending growth is anticipated to average 5.2 percent.”
